IMRN - Immuron rises 8% as Travelan and Protectyn sales increases by 431%
- Immuron ( NASDAQ: IMRN ) announces North America, Travelan sales were up by 494%, reaching AU $0.6M in FY22, compared to AU $0.1M in FY21.
- Global sales of Travelan and Protectyn increased by 431% in the 2022 fiscal year to AU $0.9M, compared to AU $0.2M in FY21.
- In the US, Travelan sales were AU $0.6M for FY22 compared to only AU $4K in FY21. This growth was attributable to increasing sales in both Passport Health Travel Clinics and on the Amazon e- commerce channel. While not at pre-pandemic peak, the sales numbers in the US are starting to considerably pick up again.
- In Australia, Travelan and Protectyn sales increased to AU $0.3M in FY22 representing a significant increase over FY21 (AU $0.1M).
- IMRN +7.6% premarket to $2.69
- Source: Press Release
For further details see:
Immuron rises 8% as Travelan and Protectyn sales increases by 431%